- Home
- IRON vs CAPL Comparison
IRON vs CAPL Comparison
Compare IRON & CAPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- CAPL
- Stock Information
- Founded
- IRON 2017
- CAPL 1992
- Country
- IRON United States
- CAPL United States
- Employees
- IRON N/A
- CAPL N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- CAPL Oil Refining/Marketing
- Sector
- IRON Health Care
- CAPL Energy
- Exchange
- IRON Nasdaq
- CAPL Nasdaq
- Market Cap
- IRON 1.8B
- CAPL 829.8M
- IPO Year
- IRON N/A
- CAPL 2012
- Fundamental
- Price
- IRON $54.04
- CAPL $20.95
- Analyst Decision
- IRON Strong Buy
- CAPL
- Analyst Count
- IRON 10
- CAPL 0
- Target Price
- IRON $93.40
- CAPL N/A
- AVG Volume (30 Days)
- IRON 417.5K
- CAPL 25.6K
- Earning Date
- IRON 08-07-2025
- CAPL 08-06-2025
- Dividend Yield
- IRON N/A
- CAPL 10.09%
- EPS Growth
- IRON N/A
- CAPL 30.34
- EPS
- IRON N/A
- CAPL 0.80
- Revenue
- IRON N/A
- CAPL $3,694,780,000.00
- Revenue This Year
- IRON N/A
- CAPL N/A
- Revenue Next Year
- IRON N/A
- CAPL N/A
- P/E Ratio
- IRON N/A
- CAPL $26.12
- Revenue Growth
- IRON N/A
- CAPL N/A
- 52 Week Low
- IRON $30.82
- CAPL $18.43
- 52 Week High
- IRON $68.73
- CAPL $25.73
- Technical
- Relative Strength Index (RSI)
- IRON 62.38
- CAPL 35.55
- Support Level
- IRON $49.73
- CAPL $21.02
- Resistance Level
- IRON $55.02
- CAPL $21.68
- Average True Range (ATR)
- IRON 2.50
- CAPL 0.58
- MACD
- IRON 0.25
- CAPL -0.04
- Stochastic Oscillator
- IRON 85.43
- CAPL 10.59
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.